Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Investigating Auto-Injector Problems With Copaxone Generics

Executive Summary

Reports of bent needles and injector failures also raise questions about the FDA’s complex product approval process.

You may also be interested in...



Was Apokyn Safety Update A Missed Opportunity For Supernus To Hold Off Generic Refill Cartridge?

US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.

Califf: More Learning Necessary During Generic Drug Lifecycle

The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.

Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies

Cyltezo won’t be available until 2023 due to patent settlement with AbbVie. The second-ever interchangeable biosimilar approved by the US FDA also contains a first: published data from a switch trial.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel